ZOVIRAX TAB 200MG TABLET

Country: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

ACYCLOVIR

Disponibbli minn:

GLAXOSMITHKLINE INC

Kodiċi ATC:

J05AB01

INN (Isem Internazzjonali):

ACYCLOVIR

Dożaġġ:

200MG

Għamla farmaċewtika:

TABLET

Kompożizzjoni:

ACYCLOVIR 200MG

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

100

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

NUCLEOSIDES AND NUCLEOTIDES

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0115506002; AHFS:

L-istatus ta 'awtorizzazzjoni:

CANCELLED POST MARKET

Data ta 'l-awtorizzazzjoni:

2016-01-11

Karatteristiċi tal-prodott

_2014-11-10/131-pristine-pm-zovirax.doc _
_ _
_ _
_ _
_ _
_Page 1 of 38_
PRODUCT MONOGRAPH
PR
ZOVIRAX
®
Acyclovir Oral Suspension USP, 200 mg /5 mL
Acyclovir Tablets USP, 200 mg
Antiviral Agent
GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
Date of Revision:
November 10, 2014
Submission Control No: 177766
_©_
_2014 GlaxoSmithKline Inc. All Rights Reserved _
_ZOVIRAX is a registered trademark of GlaxoSmithKline Inc. _
_2014-11-10/131-pristine-pm-zovirax.doc _
_ _
_ _
_ _
_ _
_Page 2 of 38_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
..............................................................................10
OVERDOSAGE
................................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
............................................................12
STORAGE AND STABILITY
..........................................................................................14
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................14
PART II: SCIENTIFIC INFORMATION
...............................................................................15
PHARMACEUTICAL INFORMATION
..........................................................